SCHEMBL2813207

SCHEMBL2813207

CC(C)(C)OC(=O)N1CCn2cc(-c3ccccc3O)nc2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 2/20 0.53
SMARCA4 P51532 2/20 0.53
PBRM1 Q86U86 2/20 0.53
MAPK1 P28482 1/20 0.42
P2RX7 Q99572 2/20 0.41
PARP1 P09874 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
PARP2 Q9UGN5 1/20 0.41
TERT O14746 1/20 0.41
ESR2 Q92731 1/20 0.40
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
KDM1A O60341 1/20 0.39
ACHE P22303 1/20 0.39
NR1H2 P55055 1/20 0.39
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29796413 0.81 GRM5 (0.44) MAPK1P2RX7PARP1TNKS2PARP2
SCHEMBL23390025 0.81 GRM5 (0.44) MAPK1P2RX7PARP1TNKS2PARP2
SCHEMBL4399124 0.81 GPR119 (0.46) MAPK1P2RX7GPR119NR1H2POLB
SCHEMBL15933682 0.80 GBA1 (0.52) MAPK1P2RX7CKS1BSKP1SKP2
SCHEMBL17298980 0.80 F2RL1 (0.45) P2RX7KDM1A
SCHEMBL15933469 0.78 GPR119 (0.43) MAPK1P2RX7ESR2CKS1BSKP1
SCHEMBL15933695 0.77 EGLN2 (0.48) P2RX7GPR119HTTATM
SCHEMBL15933470 0.77 NR1H2 (0.41) MAPK1ESR2CKS1BSKP1SKP2
SCHEMBL15933636 0.76 P2RX7 (0.43) P2RX7CKS1BSKP1SKP2GPR119
SCHEMBL1817445 0.76 ADORA1 (0.42) MAPK1ESR2CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691859-B2 Prenyl transferase inhibitors IPSEN PHARMA S.A.S. (FR) 2010-04-06 US disclosed
EP-1382607-B1 Prenyl transferase inhibitors IPSEN PHARMA (FR) 2009-08-19 EP disclosed
US-20080176835-A1 Prenyl Transferase Inhibitors BIOMEASURE, INCORPORATED 2008-07-24 US disclosed
US-7361656-B2 Prenyl transferase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2008-04-22 US disclosed
US-7084135-B1 Prenyl transferase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) 2006-08-01 US disclosed
US-20060142275-A1 Prenyl transferase inhibitors IPSEN PHARMA S.A.S. (FR) 2006-06-29 US disclosed
EP-1140942-B1 PRENYL TRANSFERASE INHIBITORS CONSEILS DE RECH SET D APPLIC (FR) 2004-03-10 EP disclosed
EP-1382607-A2 Prenyl transferase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176835-A1 Prenyl Transferase Inhibitors FNTA, FNTB, RCE1 SMARCA2 2545/4885SMARCA4 2402/4885PBRM1 3884/4885
US-20060142275-A1 Prenyl transferase inhibitors FNTA, FNTB, RCE1 SMARCA2 2545/4885SMARCA4 2402/4885PBRM1 3884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.